• Materials Science Improvements in Optical Components Could Improve At-Home Health Monitoring

    Feb 02 | Diagnostics World News | Researchers at the Norwegian University of Science and Technology and the University of Notre Dame have developed a new microresonator for biochemical sensing. This is big news, according to Dingding Ren and David Burghoff, co-leaders in joint research between the two institutes. More
  • New Test Overcomes Big Hurdle In Blood-Based Detection Of Alzheimer’s

    Jan 31 | Diagnostics World News | An international team of neuroscientists expect to soon be handing off development of a promising new blood test for Alzheimer’s disease neurodegeneration to a U.S.-based biomarker company. The immunoassay selectively measures brain-derived tau and was recently demonstrated to outperform both assessments of plasma total tau levels and measurements of neurofilament light chain concentration, a protein marker of nerve cell damage. More
  • First Liquid Biopsy Test for Non-Small Cell Lung Cancer, Microsoft Attempts to Transform Cancer Diagnoses and Patient Care, More

    Jan 26 | Diagnostics World News | A digital AI platform to enrich breast cancer grading and improve risk categorization; novel tests significantly reduce hospitalization costs and mortality and morbidity rates in newborns and premature infants; the first blood test superior to stool tests in detecting advanced adenomas and colorectal cancer; and more. More
  • Follow the Money: Gates Foundation Funds Diagnostic Tools for the Underserved, First Fully Remote Subspecialty Diagnostic Service, More

    Jan 24 | Diagnostics World News | Funding for a decision-support platform to enhance surveillance, detection, and triage of neglected tropical diseases and other rare infectious diseases, transcriptome-wide profiling and advanced medicinal chemistry technology, novel pathology consulting, and more. More
  • MRD If You Please: Diagnostics Targets Minimal Residual Disease

    Jan 19 | Diagnostics World News | At the J.P. Morgan Healthcare Conference last week, several diagnostics companies offered insight into their directions and plans for the coming year, and oncology diagnostics was a refrain. Across the space, test developers and researcher groups are turning their attention first to minimal residual disease (MRD) tests. Here we gather feedback from a few of the companies that presented last week. More
  • Cell-Free DNA Assay Could Make Routine Cancer Testing Feasible

    Jan 18 | Diagnostics World News | Scientists from the National University of Singapore (NUS) have discovered a blood test for monitoring cancer patients that could be done for as little as $35. The new Heatrich-BS assay sequences cell-free DNA in clinical samples that get heated to isolate cancer-specific signatures, according to Cheow Lih Feng, assistant professor at NUS’s Institute for Health Innovation & Technology and department of biomedical engineering. More
  • Emerging Tech Aims to Remove Racial Bias from Blood Measurements

    Jan 17 | Diagnostics World News | A team of researchers is pursuing new technology to address racial disparities in blood measurements. The group ultimately hopes to develop a portable wearable device, like a monitor or watch, capable of accurately and non-invasively reading blood regardless of skin tone. More
  • At J.P. Morgan, Illumina CEO Outlines GRAIL’s Successful Year, Uncertain Future

    Jan 12 | Diagnostics World News | In a somewhat subdued presentation compared to years past, Illumina CEO Francis deSouza kicked off his annual J.P. Morgan Healthcare Conference talk highlighting the breadth of the genomics market. deSouza sees a $120 billion total addressable market for Illumina, with oncology testing representing more than half of the opportunity. More
  • Laser-Powered Patch Monitors Hemoglobin In Deep Tissues

    Jan 10 | Diagnostics World News | Laser diodes many times stronger than the brightness of light-emitting diodes found on the back of Apple Watches and Fitbits are enabling development of a photoacoustic skin patch capable of continuously monitoring the amount and location of hemoglobin in deep tissues. This opens the possibility of noninvasively detecting organ dysfunction, cerebral or gut hemorrhages, cancer, and COVID complications with the convenience of a wearable. More
  • Trendspotting: Top Diagnostics Issues in 2023

    Jan 05 | Diagnostics World News | We spoke with various companies in the Diagnostics World community to gain insights and predictions for the coming year. They predicted faster and more precise diagnostic testing, enhanced whole genome screening, novel therapies that empower patients to direct their healthcare journey, and more advances in proteomics. More
View more articles

 
DXX-Industry-spotlight

bioready-citrate-gold-nanoshells


BioReady Citrate Gold Nanoshells

If you are looking for a probe that offers increased sensitivity, lower antibody usage, and the convenience of passive conjugation, you’ve come to the right place. Introducing BioReady Citrate Gold Nanoshells, enabling enhanced sensitivity for your lateral flow assay.

Learn more